New Buy Rating for Gilead Sciences (GILD), the Healthcare Giant

Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILDResearch Report) today and set a price target of $88. The company’s shares opened today at $64.73.

According to TipRanks.com, Syed is a 4-star analyst with an average return of 4.2% and a 58.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $82.60, which is a 27.6% upside from current levels. In a report issued on March 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $87 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $80.90 and a one-year low of $60.32. Currently, Gilead Sciences has an average volume of 7.79M.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. Last month, Gayle Wilson, a Director at GILD sold 19,068 shares for a total of $1,278,891.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.